Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4 ‐ IgG ‐Positive NMOSD
Annals of Clinical and Translational Neurology · 2026-11 · 13 (11) · 2336-2346
DOI: 10.1002/acn3.70412 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 24.04.2026. Verfasst von Jie Lin und 11 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Neuromyelitis Optica, Rituximab, Antibodies, Monoclonal, Humanized, Immunologic Factors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Plan Project of Wenzhou Municipality.
Abstract (Originalsprache)
Objective
Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited. This study aimed to evaluate the real‐world comparative effectiveness and safety of RTX versus INE.
Design
This was a retrospective, multicenter, observational study.
Methods
In this retrospective cohort study, 103 patients with AQP4‐IgG+ NMOSD were included, of whom 40 received INE and 63 received RTX. Overlap weighting based on propensity scores was employed to balance baseline covariates, achieving excellent balance (all standardized mean differences < 0.001). The primary outcomes included annualized relapse rate (ARR) and relapse risk, which were analyzed using weighted Poisson regression and Anderson‐Gill mode.
Results
After weighting, the proportion of patients experiencing any relapse was lower in the INE group than in the RTX group (10.6% vs. 43.9%, p = 0.047). In models accounting for differences in follow‐up duration, INE was also associated with a lower post‐treatment relapse risk than RTX. Although the restricted mean survival time difference at 27 months favored INE, the difference was not statistically significant. Disability progression was similar between groups, though hypogammaglobulinemia, particularly reduced IgG levels, was more frequently observed with INE (54.1% vs. 17.2%; p < 0.001).
Conclusions
In this real‐world cohort, INE showed a trend toward lower relapse risk compared to RTX, whereas demonstrating a manageable safety profile with increased incidence of hypogammaglobulinemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Taizhou Hospital, Taizhou, China.
- The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Wenzhou People's Hospital, Wenzhou, China.
- Ruian People's Hospital, Wenzhou, China.
- Yueqing People's Hospital, Wenzhou, China.
Förderung
- Science and Technology Plan Project of Wenzhou Municipality
Zitieren
APA
Lin, J., Xue, B., Xie, D., Li, J., Pan, J., Zhu, L., Tong, Q., Lin, J., Zhu, R., Zhang, X., Xia, J., & Li, X. (2026). Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4 ‐ IgG ‐Positive NMOSD. Annals of Clinical and Translational Neurology, 13(11), 2336-2346. https://doi.org/10.1002/acn3.70412
Vancouver
Lin J, Xue B, Xie D, Li J, Pan J, Zhu L, et al. Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4 ‐ IgG ‐Positive NMOSD. Annals of Clinical and Translational Neurology. 2026;13(11):2336-2346. doi:10.1002/acn3.70412
BibTeX
@article{Lin2026,
author = {Lin, Jie and Xue, Binbin and Xie, Dewei and Li, Jia and Pan, Juyuan and Zhu, Lanbing and Tong, Qiaowen and Lin, Jing and Zhu, Ruofan and Zhang, Xu and Xia, Junhui and Li, Xiang},
title = {Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4 ‐ IgG ‐Positive NMOSD},
journal = {Annals of Clinical and Translational Neurology},
year = {2026},
volume = {13},
number = {11},
pages = {2336--2346},
doi = {10.1002/acn3.70412}
}
EUVIMED